ETA for results, page-13

Funding is always an issue with small biotechs - BIT is not alone there.

Remember that any partnerships or say, phase 3 trial funding will only cover the trial costs - not the company's general operations costs. Some costs can be massaged into the trial costs - some staff costs and so other minor costs. BIT will still need to raise cash for these operational costs.

BIT only has funds for the first quarter of 2024 - plus the $1mil tax rebate which will bet through a main part of the following quarter.

So financially, funding should be at the forefront of BT's management - and I suspect it is anyway.